Patient Reported Ease-of-Use with a Disposable Autoinjector in Individuals with Migraine

PURPOSE: Erenumab-aooe (erenumab, Aimovig(®))—a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor—is approved for the prevention of migraine in adults in a number of countries. The approved monthly dosage of erenumab (70 and/or 140 mg, depending on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mead, Jennifer, Dammerman, Ryan, Rasmussen, Soeren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354909/
https://www.ncbi.nlm.nih.gov/pubmed/32753854
http://dx.doi.org/10.2147/PPA.S248584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354909/
https://www.ncbi.nlm.nih.gov/pubmed/32753854
http://dx.doi.org/10.2147/PPA.S248584

Ejemplares similares